Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas

Reuters

10/20

Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas

Hansoh Pharmaceutical Group Co., Ltd. has announced the presentation of phase 2 clinical trial results for HS-20093, a B7-H3-targeted antibody-drug conjugate $(ADC)$, in patients with relapsed or refractory (R/R) sarcomas. The data were presented at the ESMO 2025 Annual Meeting in Berlin on October 19, 2025. In the study, HS-20093 administered at 12 mg/kg every three weeks demonstrated a higher confirmed objective response rate and disease control rate in R/R osteosarcoma patients compared to the 8 mg/kg group. The 12 mg/kg group showed a confirmed objective response rate of 20.0% and a disease control rate of 86.7%, with a median progression-free survival of 8.4 months and a 15-month overall survival rate of 85.7%. In patients with soft tissue sarcoma (STS), the confirmed objective response rate was 23.1% and the disease control rate was 92.3%, with a median progression-free survival of 9.4 months and median overall survival of 22.6 months. The safety profile was deemed manageable, with no new safety signals identified. A confirmatory phase 3 study for HS-20093 in R/R osteosarcoma is ongoing in China, while early clinical development continues outside China under the name GSK5764227.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2576007101"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576007101\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576007101?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 08:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576007101","market":"us","top_or_hot":-1,"title":"Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co., Ltd. has announced the presentation of phase 2 clinical trial results for HS-20093, a B7-H3-targeted antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in patients with relapsed or refractory (R/R) sarcomas. The data were presented at the ESMO 2025 Annual Meeting in Berlin on October 19, 2025. In the study, HS-20093 administered at 12 mg/kg every three weeks demonstrated a higher confirmed objective response rate and disease control rate in R/R osteosarcoma patients compared to the 8 mg/kg group. The 12 mg/kg group showed a confirmed objective response rate of 20.0% and a disease control rate of 86.7%, with a median progression-free survival of 8.4 months and a 15-month overall survival rate of 85.7%. In patients with soft tissue sarcoma (STS), the confirmed objective response rate was 23.1% and the disease control rate was 92.3%, with a median progression-free survival of 9.4 months and median overall survival of 22.6 months. The safety profile was deemed manageable, with no new safety signals identified. A confirmatory phase 3 study for HS-20093 in R/R osteosarcoma is ongoing in China, while early clinical development continues outside China under the name GSK5764227.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-20 08:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Co., Ltd. has announced the presentation of phase 2 clinical trial results for HS-20093, a B7-H3-targeted antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, in patients with relapsed or refractory (R/R) sarcomas. The data were presented at the ESMO 2025 Annual Meeting in Berlin on October 19, 2025. In the study, HS-20093 administered at 12 mg/kg every three weeks demonstrated a higher confirmed objective response rate and disease control rate in R/R osteosarcoma patients compared to the 8 mg/kg group. The 12 mg/kg group showed a confirmed objective response rate of 20.0% and a disease control rate of 86.7%, with a median progression-free survival of 8.4 months and a 15-month overall survival rate of 85.7%. In patients with soft tissue sarcoma (STS), the confirmed objective response rate was 23.1% and the disease control rate was 92.3%, with a median progression-free survival of 9.4 months and median overall survival of 22.6 months. The safety profile was deemed manageable, with no new safety signals identified. A confirmatory phase 3 study for HS-20093 in R/R osteosarcoma is ongoing in China, while early clinical development continues outside China under the name GSK5764227.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL7gbp5W:1","article_id":"2576007101","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576007101","pubTimestamp":1760920554,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hansoh Pharmaceutical Group Co., Ltd. has announced the presentation of phase 2 clinical trial results for HS-20093, a B7-H3-targeted antibody-drug conjugate , in patients with relapsed or refractory (R/R) sarcomas. The data were presented at the ESMO 2025 Annual Meeting in Berlin on October 19, 2025. In the study, HS-20093 administered at 12 mg/kg every three weeks demonstrated a higher confirmed objective response rate and disease control rate in R/R osteosarcoma patients compared to the 8 mg/kg group. The 12 mg/kg group showed a confirmed objective response rate of 20.0% and a disease control rate of 86.7%, with a median progression-free survival of 8.4 months and a 15-month overall survival rate of 85.7%. In patients with soft tissue sarcoma , the confirmed objective response rate was 23.1% and the disease control rate was 92.3%, with a median progression-free survival of 9.4 months and median overall survival of 22.6 months. The safety profile was deemed manageable, with no new sa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1191":"制药","BK1589":"北水核心资产","03692":"翰森制药"},"translate_title":"豪森制药报告HS-20093治疗复发性或难治性肉瘤的2期结果令人鼓舞","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Hansoh Pharma Reports Promising Phase 2 Results for HS-20093 in Relapsed or Refractory Sarcomas\n    \n\n        Hansoh Pharmaceutical Group Co., Ltd. has announced the presentation of phase 2 clinical trial results for HS-20093, a B7-H3-targeted antibody-drug conjugate $(ADC)$, in patients with relapsed or refractory (R/R) sarcomas. The data were presented at the ESMO 2025 Annual Meeting in Berlin on October 19, 2025. In the study, HS-20093 administered at 12 mg/kg every three weeks demonstrated a higher confirmed objective response rate and disease control rate in R/R osteosarcoma patients compared to the 8 mg/kg group. The 12 mg/kg group showed a confirmed objective response rate of 20.0% and a disease control rate of 86.7%, with a median progression-free survival of 8.4 months and a 15-month overall survival rate of 85.7%. In patients with soft tissue sarcoma (STS), the confirmed objective response rate was 23.1% and the disease control rate was 92.3%, with a median progression-free survival of 9.4 months and median overall survival of 22.6 months. The safety profile was deemed manageable, with no new safety signals identified. A confirmatory phase 3 study for HS-20093 in R/R osteosarcoma is ongoing in China, while early clinical development continues outside China under the name GSK5764227.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on October 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}